Biodexa Pharmaceuticals (STU:5MP2) EPS (Basic): €-124.17 (TTM As of Dec. 2025)


STU:5MP2 Biodexa Pharmaceuticals PLC STU:5MP2
10 GF Score
Price €110,400.00
GF Value €95,593.41
View Full Analysis

What is Biodexa Pharmaceuticals EPS (Basic)?

Biodexa Pharmaceuticals STU:5MP2 10 EPS (Basic) is €-124.17 as of Dec. 2025. GuruFocus rates STU:5MP2 with a GF Score™ of 10/100 and a GF Value™ of €95,593.41.

Biodexa Pharmaceuticals's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €-6.53. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €-124.17.

Biodexa Pharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was €-6.53. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-124.17.

Biodexa Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2025 was €-10.61. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -131.48.

During the past 3 years, the average EPS without NRI Growth Rate was 94.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 89.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 74.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Biodexa Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 95.30% per year. The lowest was 27.50% per year. And the median was 52.00% per year.

Biodexa Pharmaceuticals  (STU:5MP2) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Biodexa Pharmaceuticals EPS (Basic) Related Terms

Biodexa Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals EPS (Basic) Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -800,265.96 -891,108.40 -580.38 -30.18 -2.86

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20,313.29 -590.97 -218.59 -117.64 -6.53
STU:5MP2
10GF Score
Biodexa Pharmaceuticals PLC STU:5MP2
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Biodexa Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.298-0)/0.022
=-331.73

Biodexa Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.947-0)/0.452
=-6.52

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-124.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-124.17 mean?
Biodexa Pharmaceuticals (STU:5MP2) has a EPS (Basic) of €-124.17 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' EPS (Basic) too high?
Biodexa Pharmaceuticals' current EPS (Basic) is €-124.17. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' EPS (Basic) compare to CASIF and OGEN?
Biodexa Pharmaceuticals' EPS (Basic) of €-124.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current EPS (Basic) is €-124.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (STU:5MP2) has a current EPS (Basic) of €-124.17. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current EPS (Basic) is €-124.17. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current EPS (Basic) is €-124.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.

Key valuation signals for STU:5MP2:

  • EPS (Basic): €-124.17
  • GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
  • GF Score™: 10/100

No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Other Exchanges BDRX:USA
Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
10GF Score

Get the complete analysis for STU:5MP2

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€110,400.00
Price
€95,593.41
GF Value